5 October 2022 - Report will be subject of Midwest CEPAC meeting in April 2023; Draft Scoping Document open to public comment until October 26, 2022.

ICER announced today that it will assess the comparative clinical effectiveness and value of resmetirom (Madrigal Pharmaceuticals) and obeticholic acid (Ocaliva, Intercept Pharmaceuticals) for non-alcoholic steatohepatitis.

Read ICER announcement